icad inc. (ICAD): Price and Financial Metrics

icad inc. (ICAD): $1.49

0.10 (-6.29%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

ICAD Price/Volume Stats

Current price $1.49 52-week high $3.97
Prev. close $1.59 52-week low $1.05
Day low $1.49 Volume 228,400
Day high $1.65 Avg. volume 211,204
50-day MA $1.57 Dividend yield N/A
200-day MA $1.81 Market Cap 39.27M

ICAD Stock Price Chart Interactive Chart >

ICAD POWR Grades

  • Sentiment is the dimension where ICAD ranks best; there it ranks ahead of 97.71% of US stocks.
  • The strongest trend for ICAD is in Quality, which has been heading down over the past 26 weeks.
  • ICAD ranks lowest in Momentum; there it ranks in the 4th percentile.

ICAD Stock Summary

  • The ratio of debt to operating expenses for ICAD INC is higher than it is for about just 6.23% of US stocks.
  • With a year-over-year growth in debt of -82.8%, ICAD INC's debt growth rate surpasses merely 1.89% of about US stocks.
  • Revenue growth over the past 12 months for ICAD INC comes in at -24.11%, a number that bests merely 11.49% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ICAD, based on their financial statements, market capitalization, and price volatility, are ACRX, NURO, GNSS, APDN, and RPID.
  • Visit ICAD's SEC page to see the company's official filings. To visit the company's web site, go to www.icadmed.com.

ICAD Valuation Summary

  • ICAD's price/earnings ratio is -4.7; this is 116.12% lower than that of the median Healthcare stock.
  • Over the past 243 months, ICAD's price/sales ratio has gone down 17.2.

Below are key valuation metrics over time for ICAD.

Stock Date P/S P/B P/E EV/EBIT
ICAD 2023-12-29 2.1 1.5 -4.7 -2.8
ICAD 2023-12-28 2.1 1.5 -4.6 -2.7
ICAD 2023-12-27 2.2 1.6 -5.0 -3.1
ICAD 2023-12-26 2.2 1.6 -4.9 -3.0
ICAD 2023-12-22 2.0 1.4 -4.5 -2.6
ICAD 2023-12-21 2.0 1.4 -4.4 -2.5

ICAD Growth Metrics

    The year over year price growth rate now stands at -81.39%.
  • Its 5 year net cashflow from operations growth rate is now at -29.84%.
  • Its 3 year net income to common stockholders growth rate is now at -39.08%.
ICAD's revenue has moved down $4,788,000 over the prior 15 months.

The table below shows ICAD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 29.262 -11.207 -14.707
2022-06-30 32.267 -10.84 -12.985
2022-03-31 32.518 -10.294 -13.147
2021-12-31 33.638 -9.408 -11.245
2021-09-30 36.282 -8.763 -8.702
2021-06-30 34.05 -8.989 -8.323

ICAD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ICAD has a Quality Grade of C, ranking ahead of 38.2% of graded US stocks.
  • ICAD's asset turnover comes in at 0.555 -- ranking 80th of 186 Medical Equipment stocks.
  • TTOO, IRMD, and DYNT are the stocks whose asset turnover ratios are most correlated with ICAD.

The table below shows ICAD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.555 0.714 -0.737
2021-03-31 0.561 0.728 -0.590
2020-12-31 0.628 0.719 -1.587
2020-09-30 0.653 0.736 -1.431
2020-06-30 0.695 0.752 -1.339
2020-03-31 0.769 0.754 -1.337

ICAD Price Target

For more insight on analysts targets of ICAD, see our ICAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1.31 (Strong Buy)

icad inc. (ICAD) Company Bio


iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.


ICAD Latest News Stream


Event/Time News Detail
Loading, please wait...

ICAD Latest Social Stream


Loading social stream, please wait...

View Full ICAD Social Stream

Latest ICAD News From Around the Web

Below are the latest news stories about ICAD INC that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

iCAD Expands Executive Sales Leadership Team as Business Grows

Bill Keyes shifts and expands his role to Senior Vice President, Global Sales Operations and Peter Graham joins iCAD as Senior Vice President, North American Sales to accelerate growth while organization adds new products and partnerships.NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales leadership with the addition of Peter Graham, as Senior Vice Presi

Yahoo | December 18, 2023

Wealth Accumulation: 3 Stocks with Multibagger Potential

While it’s never easy to identify multibagger stocks, this may be one of the best times in decades to “swing for the fences” by buying undervalued growth names that are well-positioned to at least triple over the next few years. Amid excessive worries about interest rates, the Street has pushed down many unprofitable, high-potential companies’ stocks to absurdly low levels. Now that those fears are dissipating, these firms are well-positioned to make huge comebacks. Interest rates recently dropp

Yahoo | December 5, 2023

iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow and support clinicians in delivering more personalized breast care, including cancer detection, density assessment, and recommendations NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions

Yahoo | November 28, 2023

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast canceriCAD unveils new solution that assesses calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women in the U.S.Dr. Emily Conant, Perelman School of Medicine, University of Pennsylvania, to present how iCAD’s 4th generation Breast AI is harnessing inn

Yahoo | November 27, 2023

Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive Returns

As the Street realizes that we're in the early stages of the business cycle, penny stocks should boom.

Larry Ramer on InvestorPlace | November 22, 2023

Read More 'ICAD' Stories Here

ICAD Price Returns

1-mo 2.76%
3-mo -3.25%
6-mo -22.80%
1-year 17.32%
3-year -92.04%
5-year -64.52%
YTD -15.82%
2023 -3.28%
2022 -74.58%
2021 -45.45%
2020 69.88%
2019 110.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!